Invuity Reports 2017 Third Quarter Financial Results
SAN FRANCISCO, CA–(Marketwired – Nov 7, 2017) – Invuity, Inc. (NASDAQ: IVTY), a leading medical technology company focused on minimal access surgery, today reported financial results for the quarter ended September 30, 2017.
Q3 2017 Highlights
- Revenue grew 13% to $9.6 million compared to revenue of $8.5 million in the third quarter of 2016.
- Disposable revenue grew 17% to $7.5 million compared to $6.4 million in the third quarter of 2016.
- Approximately 845 hospitals purchased Invuity devices in the third quarter of 2017, up from approximately 700 hospitals in the third quarter of 2016.
- PhotonBlade full launch was completed in the third quarter of 2017.
“In the third quarter we made significant progress in broadening our offering of our high value surgical products. I am particularly excited about the full launch of PhotonBlade, and the early strong positive feedback from surgeons is very encouraging,” said President and Chief Executive Officer Philip Sawyer. “Although sales were modestly impacted from hurricanes in the quarter, our continued growth underscores surgeons’ confidence in our products that enable superior results in minimal access surgeries.”
Revenue was $9.6 million in the third quarter of 2017, up 13% from revenue of $8.5 million in the third quarter of 2016 driven by an increase in active accounts. Management estimates that approximately $400,000 in revenue was lost due to the impact of hurricanes.
Gross margin for the third quarter was 69.9%. Gross margin was impacted by manufacturing overhead variances and to a lesser degree, early revenues from PhotonBlade and PhotonVue. Gross margin was 73.8% for the same period in 2016.
Total operating expenses for the third quarter were $15.1 million, compared to $14.6 million in the prior year period.
The net loss for the third quarter of 2017 was $8.9 million, or $0.52 loss per share, compared to a net loss of $8.8 million, or $0.56 loss per share, for the third quarter of 2016.
The Company’s balance sheet as of September 30, 2017 included total cash, cash equivalents and short-term investments of $28.8 million.
Invuity is narrowing its revenue guidance for 2017 to $40 million to $41 million.
Invuity’s management will discuss the Company’s financial results for the third quarter ended September 30, 2017, and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, November 7, 2017. To join the live call, participants may dial 1-877- 556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 3597539. To listen to the live call via Invuity’s website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company’s patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2017. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company’s devices; the Company’s ability to demonstrate to and gain approval from hospitals to use the Company’s devices; the highly competitive business environment for surgical medical devices; the Company’s ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company’s intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company’s business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Risk Factors,” which are on file with the Securities and Exchange Commission.
|Condensed Consolidated Statements of Operations|
|(In thousands, except share and per share amounts)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Cost of goods sold||2,888||2,219||8,002||6,416|
|Research and development||2,326||2,471||7,165||7,412|
|Selling, general and administrative||12,790||12,134||41,847||38,885|
|Total operating expenses||15,116||14,605||49,012||46,297|
|Loss from operations||(8,404||)||(8,346||)||(28,623||)||(29,607||)|
|Other income (expense), net||(9||)||30||(188||)||61|
|Loss on extinguishment of debt||–||–||(2,303||)||–|
|Net loss and comprehensive loss||$||(8,907||)||$||(8,821||)||$||(32,511||)||$||(31,060||)|
|Net loss per common share, basic and diluted||$||(0.52||)||$||(0.56||)||$||(1.91||)||$||(2.19||)|
|Weighted-average shares used to compute net loss per common share, basic and diluted||17,093,183||15,690,785||17,016,312||14,173,534|
|Condensed Balance Sheets|
|as of September 30, 2017 and December 31, 2016|
|(In thousands, except share and per share amounts)|
|September 30,||December 31,|
|Cash and cash equivalents||$||24,338||$||28,300|
|Restricted cash – current||181||181|
|Accounts receivable, net||6,236||5,782|
|Prepaid expenses and other current assets||1,634||1,088|
|Total current assets||43,382||51,140|
|Property and equipment, net||7,430||8,286|
|Other long-term assets||333||–|
|Liabilities and Stockholders’ Equity|
|Accrued and other current liabilities||5,934||6,351|
|Total current liabilities||14,964||9,905|
|Commitments and contingencies (Note 8)|
|Preferred stock, $0.001 par value–10,000,000 shares authorized at September 30, 2017 and December 31, 2016, no shares issued and outstanding at September 30, 2017 and December 31, 2016||–||–|
|Common stock, $0.001 par value–100,000,000 shares authorized at September 30, 2017 and December 31, 2016 17,123,856 and 16,950,940 shares issued and outstanding at September 30, 2017 and December 31, 2016||17||17|
|Additional paid-in capital||184,109||180,647|
|Total stockholders’ equity||5,399||34,448|
|Total liabilities and stockholders’ equity||$||52,054||$||60,335|